WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

N NERVOUS SYSTEM
N04 ANTI-PARKINSON DRUGS

This group comprises preparations used in the treatment of Parkinsons disease and related conditions, including drug-induced parkinsonism.

The DDDs are based on recommended doses for the long-term treatment of symptoms of Parkinsons disease.
No separate DDDs are established for oral depot formulations.


N04B DOPAMINERGIC AGENTS
N04BC Dopamine agonists

Bromocriptine used in parkinsonism is classified in this group (e.g. tablets of 5 mg and 10 mg). Low strength bromocriptine tablets (e.g. 2.5 mg) used as a prolactine inhibitor are classified in G02CB - Prolactine inhibitors.
Cabergoline used in parkinsonism is classified in this group (e.g. tablets of 1 mg). Low strength cabergoline tablets (0.5 mg) used as a prolactine inhibitor are classified in G02CB.
Lisuride in high strength formulations (e.g. 0.2 mg tablets), which is also used in the treatment of Parkinsonism, are classified in G02CB while lisuride in low strength formulations (e.g. 25 mcg tablets) are classified in N02CA.


    ATC code  Name  DDD  U Adm.R Note
    N04BC01 bromocriptine 40 mg 

List of abbreviations

Last updated: 2024-01-26